undefined

Sam Fazeli

Director of Research at Bloomberg Intelligence, PhD in pharmacology. Expert in public health and vaccine-related issues.

Top 10 podcasts with Sam Fazeli

Ranked by the Snipd community
undefined
Aug 16, 2024 • 37min

US Consumer Sentiment Rises For First Time in Five Months

Joanne Hsu, Director of the University of Michigan Surveys of Consumers, reveals an uptick in consumer sentiment and its economic implications. Shana Sissel, President and CEO of Banríon Capital Management, shares her take on market volatility and investment strategies. Sam Fazeli, Senior Pharmaceuticals Director at Bloomberg Intelligence, discusses recent developments in the biotech industry, including the Mpox outbreak. Ana Cabral, CEO of Sigma Lithium, highlights the company's sustainable mining practices, essential for the green energy transition.
undefined
Nov 22, 2024 • 8min

Here's Why Vaccine Hesitancy Is A Growing Problem

Sam Fazeli, Director of Research at Bloomberg Intelligence with a PhD in pharmacology, tackles the concerning rise in vaccine hesitancy, particularly for childhood immunizations. He discusses the alarming implications of appointing a vaccine-skeptic to a key health position, highlighting the historical context and recent measles outbreaks. Fazeli emphasizes the need for transparency in vaccine approval processes to build public trust and explores how health policies can either enhance or undermine vaccine uptake amid political pressures.
undefined
Nov 1, 2024 • 37min

US Tech Earnings, Commercial MBS Bonds Go Bust

Mandeep Singh, senior tech analyst, shares insights on Alphabet's strong earnings amid Meta's AI concerns. Sam Fazeli discusses Eli Lilly's challenges in the pharmaceutical market. Corey Cantor highlights the impact of U.S. presidents on EV fuel economy standards. Carmen Arroyo reveals the fragility of the commercial mortgage-backed securities market, particularly in U.S. office spaces. Alison Williams analyzes UBS's earnings, while Rhett Buttle emphasizes business leaders' roles in advocating for secure elections, showcasing the intersection of finance and civic responsibility.
undefined
Oct 30, 2024 • 32min

Super Micro Auditor Resigns, Eli Lilly Cuts Outlook

Woo Jin Ho, a Senior Technology Analyst, discusses the shocking resignation of Super Micro's auditor and its impact on the AI market. Alison Williams analyzes UBS's strong performance compared to European banks, showcasing its robust equities business. Sam Fazeli dissects Eli Lilly's disappointing earnings and the challenges they face with obesity drug demand. Mandeep Singh highlights Google's impressive performance in a competitive cloud market. Laura Davison shares insights on Puerto Rico's increasing political significance in U.S. elections, including recent controversies and voter integrity issues.
undefined
Aug 23, 2024 • 38min

US Retail Earnings, Weight Loss Drug

Joining the discussion are Sam Fazeli, Director of Research at Bloomberg Intelligence, who shares insights from a study showing Eli Lilly's weight-loss drug significantly lowers diabetes risk. Mary Ross Gilbert analyzes Macy's and TJX earnings, revealing shifts in consumer habits. Jennifer Bartashus highlights Target's impressive sales recovery through strategic initiatives. They also touch on potential retail mergers impacting convenience stores, all while keeping an eye on the evolving retail landscape amidst economic pressures.
undefined
Aug 20, 2024 • 43min

Lilly’s Zepbound Cuts Risk of Diabetes

Sam Fazeli, Director of Research for Global Industries at Bloomberg Intelligence, reveals how Eli Lilly’s Zepbound drug significantly reduces diabetes risk. Craig Trudell discusses the European Union's looming 9% tariff on Tesla imports from China, raising concerns about market competitiveness. Dryden Pence shares insights on current market dynamics and investment strategies, including how labor data and consumer trends are shifting the landscape, while also highlighting opportunities in AI venture capital.
undefined
Jul 12, 2024 • 36min

Eli Lilly, Morphic Deal, Delta Earnings

Sam Fazeli discusses Eli Lilly acquiring Morphic for $3.2 billion. Mandeep Singh talks about Microsoft and Apple stepping back from OpenAI roles. George Ferguson covers Delta Airlines earnings. Tim Craighead highlights 10 companies to watch in 3Q. Martin Tengler explores the importance of hydrogen in a green future.
undefined
Jul 8, 2024 • 47min

Eli Lilly to Purchase Morphic, Green Hydrogen

Sam Fazeli discusses Eli Lilly acquiring Morphic. Sean O'Hara talks about the ETF market. Jared Dillian advises investors. The show covers pharmaceutical acquisitions, market stability, green hydrogen, and investment strategies.
undefined
Apr 30, 2024 • 59min

Episode 99

Biotech Hangout hosts discuss Biden's capital gains tax proposal, FTC's non-compete ban, Q1 earnings reports, Acrivon's oncology data, ImmunityBio's FDA approval, and financings like Xaira Therapeutics $1B raise. They also debate liked vs unliked CEOs and delve into innovative biotech approaches in depression and obesity treatment, as well as biotech deals and investments.
undefined
Nov 8, 2023 • 38min

CT Finances, Yields, Obesity Drugs, and Cars

Sean Scanlon, State Comptroller for Connecticut, discusses Connecticut finances and fiscal spending. Sam Fazeli talks about weight loss drug development and vaccine development. Matt Smith discusses inflationary trends, market outlook, and attractiveness in yields. Philip Richter discusses the impact of higher interest rates on the collector car market.